Zhitong Finance APP learned that Pfizer Pharmaceuticals (NYSE:) (PFE.US) will announce the second quarter of 2021 earnings before the US stock market on July 28, Eastern Time. The current trading price of the stock is close to $42. The market is generally optimistic about Pfizer’s second-quarter performance. A series of strong performance data may then push the stock to an upward channel.
Performance expectations
Wall Street analysts expect Pfizer’s second-quarter earnings per share to be US$0.971, compared to US$0.780 in the same period last year; revenue is expected to be US$18.71 billion, an increase of 58.51% from the same period last year.
The well-known performance forecasting platform Trefis expects Pfizer’s revenue in the second quarter of 2021 to be approximately 21.7 billion U.S. dollars, which is 16% higher than Wall Street’s forecast. Earnings per share are expected to be $1.12, which is also higher than Wall Street’s expectations. The platform also expects adjusted earnings per share to rise from $2.22 in 2020 to $4.75 this year.
Vaccines are still the main source of revenue
With the acceleration of the economic recovery, many countries around the world are actively carrying out new crown vaccination programs. According to Trefis’s forecast, for Pfizer, its new crown vaccine is still the main driver of recent revenue growth. Pfizer’s new crown vaccine sales in the first quarter of 2021 will reach 3.5 billion U.S. dollars. Trefis predicts the new crown vaccine sales in the second quarter It will far exceed the first quarter, and Trefis expects Pfizer’s full-year product sales in 2021 to reach 35 billion U.S. dollars.
Pfizer’s pharmaceutical business may also achieve growth in the second quarter. After the lockdown policy is lifted, as the number of hospital visits increases, Pfizer’s drug demand will rebound sharply. In addition, Pfizer posted a message on its official website in March, stating that the company’s experimental oral new crown treatment drug is expected to be launched by the end of this year, and the drug is positioned as an oral drug that focuses on the treatment of mild new crown disease.
Fusion MediaOr anything withFusion MediaThe person concerned does not accept any liability for loss or damage caused by relying on the data, quotations, charts and buy/sell signals contained in this website. Please fully understand the risks and costs associated with financial market transactions. This is one of the most risky forms of investment. The English version of this agreement is the main version. If there is a discrepancy between the English version and the Chinese version, the English version shall prevail.